Actively Recruiting
Quadruple Immunotherapy for Neuroblastoma
Led by Hong Kong Children's Hospital · Updated on 2025-09-15
29
Participants Needed
1
Research Sites
208 weeks
Total Duration
On this page
Sponsors
H
Hong Kong Children's Hospital
Lead Sponsor
T
The University of Hong Kong
Collaborating Sponsor
AI-Summary
What this Trial Is About
This is a single-arm clinical trial to evaluate the efficacy and safety of quadruple immunotherapy with natural killer (NK) cells, anti-GD2 antibody, cytokines (interleukin-2 (IL-2) and granulocyte-macrophage colony stimulating factor (GM-CSF)) and retinoid X receptor gamma (RXRg) agonist spironolactone for paediatric patients with relapsed or refractory neuroblastoma.
CONDITIONS
Official Title
Quadruple Immunotherapy for Neuroblastoma
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Relapsed or refractory neuroblastoma
- Adequate organ function: creatinine clearance 640 ml/min/1.73m2, total bilirubin 63 times the upper limit of normal, ALT 500 IU/L, left ventricular shortening fraction 5%, and oxygen saturation 592% in room air
- Karnofsky or Lansky performance status score 50 or higher
- Has an appropriate HLA-haploidentical natural killer cell donor available
You will not qualify if you...
- Pregnant or lactating women
- HIV infection
- Patients for whom conventional treatment is considered more appropriate
- Patients unlikely to benefit, such as those with terminal malignancy and life expectancy less than one month
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Hong Kong Children's Hospital
Hong Kong, Hong Kong
Actively Recruiting
Research Team
D
Daniel Cheuk
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here